登录 | 注册    关注公众号  
微信公众号
搜索
 >  Protein>IGF-I R >IGR-H82E3

Biotinylated Human IGF-I R / CD221 Protein, His,Avitag™

分子别名(Synonym)

IGF1R,IGFR,JTK13,CD221,MGC142170,MGC142172,MGC18216

表达区间及表达系统(Source)

Biotinylated Human IGF-I R, His,Avitag (IGR-H82E3) is expressed from human 293 cells (HEK293). It contains AA Glu 31 - Asn 932 (Accession # P08069-1).

Request for sequence

蛋白结构(Molecular Characterization)

IGF-I R Structure

This protein carries a polyhistidine tag at the C-terminus, followed by an Avi tag (Avitag™).

The protein has a calculated MW of 106.6 kDa. The protein migrates as 40-55 kDa,60 kDa and 95-150 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.

标记(Labeling)

Biotinylation of this product is performed using Avitag™ technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.

蛋白标记度(Protein Ratio)

Passed as determined by the HABA assay / binding ELISA.

内毒素(Endotoxin)

Less than 1.0 EU per μg by the LAL method.

纯度(Purity)

>90% as determined by SDS-PAGE.

制剂(Formulation)

Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

Contact us for customized product form or formulation.

重构方法(Reconstitution)

Please see Certificate of Analysis for specific instructions.

For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

存储(Storage)

After reconstitution, this product is stable after storage at -20°C or lower.

Please avoid repeated freeze-thaw cycles.

This product is stable after storage at:

  1. -20°C to -70°C for 12 months in lyophilized state;
  2. -70°C for 3 months under sterile conditions after reconstitution.
 

电泳(SDS-PAGE)

IGF-I R SDS-PAGE

Biotinylated Human IGF-I R, His,Avitag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90% (With Star Ribbon Pre-stained Protein Marker).

 

活性(Bioactivity)-ELISA

IGF-I R ELISA

Immobilized Biotinylated Human IGF-I R, His,Avitag (Cat. No. IGR-H82E3) at 1 μg/mL (100 μL/well)on streptavidin (Cat. No. STN-N5116) precoated (0.5 μg/well) plate can bind Human IGF-I, Fc Tag with a linear range of 5-156 ng/mL (QC tested).

Protocol

 

活性(Bioactivity)-SPR

IGF-I R SPR

Biotinylated Human IGF-I R, His,Avitag (Cat. No. IGR-H82E3) immobilized on CM5 Chip can bind Human IGF-I, His Tag (Cat. No. IG1-H5245) with an affinity constant of 33.9 nM as determined in a SPR assay (Biacore 8K) (Routinely tested).

Protocol

 

背景(Background)

The Insulin-like Growth Factor 1 Receptor (IGF1) is also known as CD221, JTK13. and is a transmembrane receptor that is activated by IGF-1 and by the related growth factor IGF-2. It belongs to the large class of tyrosine kinase receptors. This receptor mediates the effects of IGF-1, which is a polypeptide protein hormone similar in molecular structure to insulin. IGF1R is make up of two alpha subunits and two beta subunits ,the Both the α and β subunits are synthesized from a single mRNA precursor. The precursor is then glycosylated, proteolytically cleaved, and crosslinked by cysteine bonds to form a functional transmembrane αβ chain.The α chains are located extracellularly while the β subunit spans the membrane and are responsible for intracellular signal transduction upon ligand stimulation. IGF1R have a binding site for ATP, which is used to provide the phosphates for autophosphorylation. There is a 60% homology between IGF1R and the insulin receptor. In response to ligand binding, the α chains induce the tyrosine autophosphorylation of the β chains. This event triggers a cascade of intracellular signaling that, while somewhat cell type specific, often promotes cell survival and cell proliferation.

 

前沿进展

 
 
货号/价格
产品推荐
文档
联系电话:
+86 400-682-2521(全国)
010-53681107(北京)
021-50850665(上海)
运输方式
订单邮箱:
order.cn@acrobiosystems.com
技术支持邮箱:
tech.cn@acrobiosystems.com
IGF-I R靶点信息
英文全称:Insulin-like growth factor I receptor
中文全称:胰岛素样生长因子-I受体
种类:Homo sapiens
上市药物数量:6详情
临床药物数量:26详情
最高研发阶段:批准上市
查看更多信息
前沿进展
点击查看详细

消息提示

请输入您的联系方式,再点击提交!

确定